As expected from the selection criteria, participants were seriously ill with high prevalence of organ dysfunction and adverse clinical markers (Figure 1), including cool peripheries, tachypnoea, use of accessory muscles of breathing, functional impairment, anaemia, kidney injury, AST elevation independent of variance in ALT, and thrombocytopenia with increased mean platelet volume (implying platelet destruction rather than bone marrow failure). This evidence concerns the gene GPT and Thrombocytopenia.